ResMed| (RMD): financials, SEC filings and peers

ResMed| (RMD) is a health care equipment company in the Health Care sector of the S&P 500, headquartered in San Diego, California.

It was founded in 1989 and joined the S&P 500 on July 26, 2017.

Its fiscal year ends in June, and its shares trade on the NYSE.

In its SEC filings it is classified as “Surgical & Medical Instruments & Apparatus”.

ResMed| at a glance

Revenue (12 months): $5.7B
Revenue growth: +9.9%
Operating margin: 33.4%
Net income (12 months): $1.5B
Free cash flow (12 months): $1.6B
Cash: $1.5B
Debt: $659M
Diluted EPS (12 months): $10.43

Twelve months to June 30, 2026, from the 10-K filed August 13, 2026.

Latest twelve months

Over the twelve months to June 30, 2026, ResMed| reported revenue of $5.7 billion, up 9.9% from a year earlier.

Its operating margin was 33.4%: for every $100 of sales, about $33 was left as operating profit.

Net income was $1.5 billion (26.9% of revenue), 8.8% higher than a year earlier.

Operating cash flow was $1.8 billion and capital spending $156 million, leaving free cash flow of $1.6 billion (29.2% of revenue).

At the end of the period it held $1.5 billion in cash and $659 million in debt, a net cash position of $810 million.

The diluted share count rose 242.4% in a year, which dilutes existing shareholders.

Five-year trend

Revenue went from $3.2 billion in fiscal 2021 to $5.7 billion in fiscal 2026, about 12.1% a year.
Revenue has grown for 5 fiscal years in a row.
Operating margin widened from 28.3% to 33.4% over the same years.
Free cash flow was positive in each of the last 6 fiscal years.

Fiscal year	2022	2023	2024	2025	2026
Revenue	$3.6B	$4.2B	$4.7B	$5.1B	$5.7B
Revenue growth	11.9%	18.0%	10.9%	9.8%	9.9%
Operating margin	28.0%	26.8%	28.2%	32.7%	33.4%
Net income	$779M	$898M	$1.0B	$1.4B	$1.5B
Free cash flow	$216M	$574M	$1.3B	$1.7B	$1.6B
Diluted EPS	$5.30	$6.09	$6.92	$9.51	$10.43

Fiscal years as reported in ResMed|’s 10-K filings. Free cash flow is operating cash flow minus capital spending.

Recent SEC filings

8-K filed September 1, 2026 — Other event
8-K filed August 17, 2026 — Auditor change; Executive or director change
10-K filed August 13, 2026 — annual report
8-K filed August 6, 2026 — Earnings results; Other event
8-K filed July 7, 2026 — Earnings results; Regulation FD disclosure
10-Q filed May 1, 2026 — quarterly report
8-K filed April 30, 2026 — Executive or director change
8-K filed April 30, 2026 — Earnings results; Other event

All ResMed| filings on SEC EDGAR

Companies like ResMed|

Other S&P 500 companies in Health Care Equipment:

More from Health Care

All 60 Health Care companies →

Questions about ResMed|

Is ResMed|'s revenue growing?

Yes. Revenue for the twelve months to June 30, 2026 was $5.7 billion, up 9.9% from a year earlier, according to its SEC filings.

Is ResMed| profitable?

Yes. It earned $1.5 billion in net income over the twelve months to June 30, 2026, a net margin of 26.9%.

Does ResMed| have more cash or more debt?

At June 30, 2026 it had $1.5 billion in cash and $659 million in debt, so more cash than debt.

When did ResMed| last file financial results?

Its latest annual report (10-K) was filed with the SEC on August 13, 2026.

Which companies are similar to ResMed|?

In the S&P 500, ResMed| is grouped in Health Care Equipment within the Health Care sector. Abbott Laboratories (ABT), Baxter International (BAX), Becton Dickinson (BDX), Boston Scientific (BSX), Dexcom (DXCM) are in the same group.

Understand the numbers

Source: ResMed|’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved September 27, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.